Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 1
2017 1
2018 2
2019 2
2020 2
2021 1
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI).
Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, Shariat SF, Rasul S. Grubmüller B, et al. Among authors: grubmuller kh. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):439-447. doi: 10.1038/s41391-020-00294-0. Epub 2020 Sep 29. Prostate Cancer Prostatic Dis. 2021. PMID: 32994534
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Grubmüller B, et al. Among authors: grubmuller kh. Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15. Prostate. 2020. PMID: 31614001
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.
Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. Grubmüller B, et al. Among authors: grubmuller kh. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26. Eur J Nucl Med Mol Imaging. 2018. PMID: 29075832 Free PMC article.
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Among authors: grubmuller kh. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.